"The Insider by DFIN" is a series of video interviews featuring the latest trends, topics and key perspectives on the global capital markets.
With Opthea Limited's U.S. listing in 2020, the company's disclosure requirements have increased significantly. It was imperative for the company, with a dual listing on ASX and NASDAQ, to find a solution that would allow them to meet the new requirements while delivering timely and accurate disclosures to their investors and regulators.
DFIN's ActiveDisclosure software provided that solution – it has helped to optimize the disclosure process by alleviating the challenges faced by the company's lean reporting team to collaborate in real-time and reduce the risk associated with manual efforts to drive best practice reporting.
In this episode of “The Insider by DFIN”, we had the opportunity to speak with Dr. Megan Baldwin, CEO and Managing Director, and Karen Adams, Vice President of Finance and Company Secretary of Opthea Limited. They highlighted the importance of an efficient disclosure process for Opthea, especially when the company has material information to share with its investors and stakeholders. We also explored how DFIN’s purpose-built compliance reporting platform ActiveDisclosure and 24/7 expert support have not only enabled Opthea to meet the latest reporting requirements, but also supported the company’s mission to improve vision for patients with retinal diseases.
- About Opthea Limited and the company’s vision
- How is Opthea addressing current gaps in the market?
- The disclosure obligations of Opthea Limited as an ASX and NASDAQ dual-listed company
- How has DFIN’s New ActiveDisclosure enabled Opthea to deliver timely and efficient disclosure to its investors and regulators
About Opthea Limited
Opthea (Nasdaq:OPT; ASX:OPT) is a biopharmaceutical company developing novel therapies to address the unmet need in the treatment of highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). Opthea’s lead product candidate OPT-302 is in pivotal Phase 3 clinical trials and being developed for use in combination with anti-VEGF-A monotherapies to achieve broader inhibition of the VEGF family, with the goal of improving overall efficacy and demonstrating superior vision gains over that which can be achieved by inhibiting VEGF-A alone. For more information, visit: https://opthea.com/
Dr. Megan Baldwin, Ph.D., CEO & Managing Director, Opthea Limited
Karen Adams, Vice President of Finance and Company Secretary, Opthea Limited
Jeff Catt, Senior Vice President of Global Sales, ActiveDisclosure by DFIN
Date of recording: February 21, 2023